Indian Drug Makers Introduce New Drugs To Thwart Asthma Drug Caps
This article was originally published in PharmAsia News
Major drug makers in India are producing new brands of a popular asthma drug in an effort to avoid the nation's price controls. Cipla, Dr. Reddy's, Ranbaxy and Zydus Cadila have brought out new brands based on doxopthyline, a derivative of theophyline, which is subject to controls. The move is being made even though doxopthyline is considered less effective, because the makers can fetch a higher price. Dr. Reddy's introduced its Doxobid, Macleods its Doxoril, Ranbaxy its Synasma and Zydus its Doxolin within the past year or so, none subject to price controls. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.